J&J Covid-19 vaccine still expected to reach target despite stalled supplies

White House promises more J&J COVID-19 shots after launch stalls Johnson & Johnson should come close to hitting its target of delivering 20 million doses of its one-shot COVID-19 vaccine in March after its shipments stalled in recent weeks, a top White House official said on Monday, while declining to say how many will go out this week. Carl O’Donnell, Michael Erman U.S.

(Reuters) - Johnson & Johnson should come close to hitting its target of delivering 20 million doses of its one-shot COVID-19 vaccine in March after its shipments stalled in recent weeks, a top White House official said on Monday, while declining to say how many will go out this week.

The company shipped four million shots in early March but its rollout has since stalled as facilities involved in the manufacturing await clearance from the U.S. Food and Drug Administration. J&J’s COVID-19 vaccine was authorized by U.S. regulators in February, making it the third to be cleared for use in the United States and the first that requires just one injection for immunization.

The healthcare conglomerate has only shipped around 4.25 million doses in total, according to federal data, far less than the 20 million it promised to deliver by the end of March. Only 2.3 million J&J doses had been administered as of Sunday morning.

“I’m not going to give you precise numbers,” White House COVID-19 adviser Andy Slavitt said on a Monday press call. “I wouldn’t signal to you that they’re going to be far away from the numbers that they have projected,” he said. J&J did not immediately respond to requests for comment. Initial U.S. doses have been made at the company’s plant in Leiden, the Netherlands. J&J has been waiting on the FDA to approve plants of outside contract manufacturers that will produce the vaccine, such as Catalent Inc.  ...